EP2026801
Deferasirox til að meðhöndla arfgengan járngeymdarkvilla
Status:
EP Einkaleyfi fallið úr gildiEP appl. date:
21.5.2007EP published:
6.11.2013EP application number:
07840190.8
EP translation filed:
18.12.2013Grant published:
15.1.2014EPO information:
European Patent Register
Max expiry date:
20.5.2027Expiry date:
20.5.2018
Title:
Deferasirox for the treatment of hereditary hemochromatosis
Timeline
Today
21.5.2007EP application
6.11.2013EP Publication
18.12.2013Translation submitted
15.1.2014Registration published
20.5.2018Expires
Owner
Name:
Novartis AGAddress:
Corporate Intellectuel Property, CH-4002, Basel, CH
Inventor
Name:
NICK, HanspeterAddress:
Duggingen, CH
Name:
ROJKJAER, LisaAddress:
Princeton, New Jersey, US
Name:
BODNER, Janet EllenAddress:
Bernardsville, New Jersey, US
Name:
MARKS, Peter WayneAddress:
Woodbridge, Connecticut, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
747974 PDate:
23.5.2006Country:
US
Number:
803049 PDate:
24.5.2006Country:
US
Number:
835658 PDate:
4.8.2006Country:
US
Classification
Categories:
A61K 31/4196, A61P 7/00, A61P 3/12, A61P 43/00
Annual fees
Number
Paid
Expires
Payer
Number: 8
Paid: 9.4.2014
Expires: 20.5.2015
Payer: Árnason Faktor
Number: 9
Paid: 9.4.2015
Expires: 20.5.2016
Payer: Árnason Faktor
Number: 10
Paid: 12.4.2016
Expires: 20.5.2017
Payer: Árnason Faktor
Number: 11
Paid: 25.4.2017
Expires: 20.5.2018
Payer: Árnason Faktor